Health Care·Biotechnology·$10.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.71 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.71 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced in the quarter. They emphasized a long-term vision but did not offer specific guidance.
Management did not provide specific guidance for future quarters.
The company is focusing on long-term strategies despite current challenges.
The earnings report indicates ongoing challenges for Arrowhead Pharmaceuticals, as evidenced by the missed EPS. The stock's significant drop of 14.15% reflects investor concerns about the company's performance and lack of guidance. Without clear direction from management, investors may remain cautious moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SAMSARA INC A
Aug 13, 2012